Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The 13th European Cancer Conference (ECCO 13)

The 13th European Cancer Conference (ECCO 13) Am J Cancer 2006; 5 (1): 61-69 MEETING REPORT 1175-6357/06/0001-0061/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. 30 October – 3 November 2005, Paris, France Andrea Bothwell and Michelle Wilde Adis International Inc., Yardley, Pennsylvania, USA The 13th European Cancer Conference (ECCO 13) was held in confirm the benefit of antiangiogenic therapy in patients with Paris, France on 30 October–3 November 2005. This biennial breast cancer. Importantly, the improvements in response rate and conference is the largest cancer conference in Europe and the progression-free survival were obtained with minimal increase in largest truly multidisciplinary cancer conference in the world. side effects. Given the benefit of bevacizumab in patients with ECCO 13 attracted >12 000 delegates from around the world, with metastatic disease, we look forward to initiating trials in the a scientific program compiled from >20 separate oncology catego- adjuvant setting.” ries. The program was designed to demonstrate how the translation 1.2 Sorafenib Promising in Metastatic Breast Cancer of basic research into practical clinical tools is successfully bring- ing new, more effective, treatments into daily hospital practices. Sorafenib has promising efficacy and is well tolerated in heavi- ly pretreated patients with metastatic breast cancer, say Italian 1. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

The 13th European Cancer Conference (ECCO 13)

Loading next page...
 
/lp/springer-journals/the-13th-european-cancer-conference-ecco-13-wmivkdLJDA
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (1): 61-69 MEETING REPORT 1175-6357/06/0001-0061/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. 30 October – 3 November 2005, Paris, France Andrea Bothwell and Michelle Wilde Adis International Inc., Yardley, Pennsylvania, USA The 13th European Cancer Conference (ECCO 13) was held in confirm the benefit of antiangiogenic therapy in patients with Paris, France on 30 October–3 November 2005. This biennial breast cancer. Importantly, the improvements in response rate and conference is the largest cancer conference in Europe and the progression-free survival were obtained with minimal increase in largest truly multidisciplinary cancer conference in the world. side effects. Given the benefit of bevacizumab in patients with ECCO 13 attracted >12 000 delegates from around the world, with metastatic disease, we look forward to initiating trials in the a scientific program compiled from >20 separate oncology catego- adjuvant setting.” ries. The program was designed to demonstrate how the translation 1.2 Sorafenib Promising in Metastatic Breast Cancer of basic research into practical clinical tools is successfully bring- ing new, more effective, treatments into daily hospital practices. Sorafenib has promising efficacy and is well tolerated in heavi- ly pretreated patients with metastatic breast cancer, say Italian 1.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References